EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Application of Immune Checkpoint Inhibitors in Cancer

Zhijun Chen, Zihan Song, Shichen Den, Wei Zhang, Mengjia Han, Tianhang Lan, Xiaokang Du, Jingyun Ning, XinHui Chen, Haoming Lin, Rui Zhang

MedComm · 2025-08 · 6 (8)

DOI: 10.1002/mco2.70176 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 10.08.2025. Verfasst von Zhijun Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 288 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a significant challenge to society and public health in the 21st century. According to GLOBOCAN 2020, there were 19.3 million new cancer cases with approximately 10.0 million deaths in 2020 globally. By 2040, 28 million new cases and 16.2 million deaths are estimated. With the escalating challenges of cancer and limitations of conventional therapies like surgery, chemotherapy, and radiotherapy, the development of novel therapies such as immunotherapy and targeted therapy is required. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has become a significant advancement in cancer treatment, combating tumors by activating the immune system. This review offers a thorough overview of ICIs, including their classification, mechanisms of action, and adverse events. It also examines the application of ICIs across various cancer types especially on advanced or unresectable malignancies, such as head and neck squamous cell carcinoma, esophageal cancer, non‐small cell lung cancer, breast cancer, hepatocellular carcinoma, and bladder cancer, highlighting their therapeutic potential and the challenges they face. By providing a comprehensive analysis, this review aims to construct a reference system for clinicians to better understand and utilize ICIs in treating cancer.

Schlagwörter

Stichwörter der Autor:innen

Advanced malignanciesAdverse eventsClinical applicationImmune checkpoint inhibitorsImmune checkpoints

Autor:innen und Institutionen

  • Department of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
  • Department of Liver Surgery Sun Yat-Sen University Cancer Center Sun Yat-sen University Guangzhou China.
  • Department of Otorhinolaryngology Sun Yat-Sen University Cancer Center Sun Yat-sen University Guangzhou China.
  • Department of Thoracic Surgery Sun Yat-Sen University Cancer Center Sun Yat-sen University Guangzhou China.
  • Breast Tumor Center Sun Yat-Sen University Cancer Center Sun Yat-sen University Guangzhou China.
  • Department of Urology Sun Yat-Sen University Cancer Center Sun Yat-sen University Guangzhou China.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Chen, Z., Song, Z., Den, S., Zhang, W., Han, M., Lan, T., Du, X., Ning, J., Chen, X., Lin, H., & Zhang, R. (2025). Application of Immune Checkpoint Inhibitors in Cancer. MedComm, 6(8). https://doi.org/10.1002/mco2.70176

Vancouver

Chen Z, Song Z, Den S, Zhang W, Han M, Lan T, et al. Application of Immune Checkpoint Inhibitors in Cancer. MedComm. 2025;6(8). doi:10.1002/mco2.70176

BibTeX
@article{Chen2025,
  author = {Chen, Zhijun and Song, Zihan and Den, Shichen and Zhang, Wei and Han, Mengjia and Lan, Tianhang and Du, Xiaokang and Ning, Jingyun and Chen, XinHui and Lin, Haoming and Zhang, Rui},
  title = {Application of Immune Checkpoint Inhibitors in Cancer},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {8},
  doi = {10.1002/mco2.70176}
}
Kostenlos starten →